X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cipla with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs SUN PHARMA - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA SUN PHARMA CIPLA/
SUN PHARMA
 
P/E (TTM) x 40.7 38.0 107.0% View Chart
P/BV x 3.7 4.2 88.7% View Chart
Dividend Yield % 0.5 0.5 83.1%  

Financials

 CIPLA   SUN PHARMA
EQUITY SHARE DATA
    CIPLA
Mar-18
SUN PHARMA
Mar-17
CIPLA/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs663842 78.7%   
Low Rs479572 83.7%   
Sales per share (Unadj.) Rs189.0131.6 143.6%  
Earnings per share (Unadj.) Rs17.632.7 53.8%  
Cash flow per share (Unadj.) Rs34.038.0 89.6%  
Dividends per share (Unadj.) Rs3.003.50 85.7%  
Dividend yield (eoy) %0.50.5 106.2%  
Book value per share (Unadj.) Rs176.7152.7 115.7%  
Shares outstanding (eoy) m805.122,399.26 33.6%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.05.4 56.2%   
Avg P/E ratio x32.521.6 150.1%  
P/CF ratio (eoy) x16.818.6 90.1%  
Price / Book Value ratio x3.24.6 69.8%  
Dividend payout %17.110.7 159.3%   
Avg Mkt Cap Rs m459,7241,696,877 27.1%   
No. of employees `00023.617.5 134.8%   
Total wages/salary Rs m26,90149,023 54.9%   
Avg. sales/employee Rs Th6,446.118,028.3 35.8%   
Avg. wages/employee Rs Th1,139.42,798.8 40.7%   
Avg. net profit/employee Rs Th600.04,479.5 13.4%   
INCOME DATA
Net Sales Rs m152,193315,784 48.2%  
Other income Rs m3,5776,232 57.4%   
Total revenues Rs m155,769322,016 48.4%   
Gross profit Rs m28,264100,893 28.0%  
Depreciation Rs m13,22812,648 104.6%   
Interest Rs m1,1423,998 28.6%   
Profit before tax Rs m17,47090,479 19.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m-2899 -28.0%   
Extraordinary Inc (Exp) Rs m-7750-   
Tax Rs m2,50112,116 20.6%   
Profit after tax Rs m14,16678,462 18.1%  
Gross profit margin %18.631.9 58.1%  
Effective tax rate %14.313.4 106.9%   
Net profit margin %9.324.8 37.5%  
BALANCE SHEET DATA
Current assets Rs m108,141329,537 32.8%   
Current liabilities Rs m38,322178,870 21.4%   
Net working cap to sales %45.947.7 96.2%  
Current ratio x2.81.8 153.2%  
Inventory Days Days9779 122.8%  
Debtors Days Days7483 89.4%  
Net fixed assets Rs m109,411204,766 53.4%   
Share capital Rs m1,6102,399 67.1%   
"Free" reserves Rs m140,682363,997 38.6%   
Net worth Rs m142,292366,397 38.8%   
Long term debt Rs m36,62114,361 255.0%   
Total assets Rs m228,606614,102 37.2%  
Interest coverage x16.323.6 68.9%   
Debt to equity ratio x0.30 656.6%  
Sales to assets ratio x0.70.5 129.5%   
Return on assets %6.713.4 49.9%  
Return on equity %10.021.4 46.5%  
Return on capital %10.024.8 40.1%  
Exports to sales %32.80-   
Imports to sales %00-   
Exports (fob) Rs m49,883NA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m51,69144,118 117.2%   
Fx outflow Rs m21,03324,484 85.9%   
Net fx Rs m30,65819,634 156.1%   
CASH FLOW
From Operations Rs m14,62870,822 20.7%  
From Investments Rs m-8,540-42,216 20.2%  
From Financial Activity Rs m-3,855-22,854 16.9%  
Net Cashflow Rs m2,4316,107 39.8%  

Share Holding

Indian Promoters % 16.0 63.7 25.1%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 5.1 237.8%  
FIIs % 23.7 23.0 103.0%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 8.3 315.7%  
Shareholders   161,166 133,026 121.2%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   PFIZER  GSK PHARMA  PANACEA BIOTECH  DR. REDDYS LAB  ABBOTT INDIA  

Compare CIPLA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 290 Points; Realty and PSU Stocks Witness Selling(Closing)

After opening the day on a negative note, share markets in India continued their downtrend throughout the day and ended in red.

Related Views on News

SUN PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 446.1% (Quarterly Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

For the quarter ended June 2018, SUN PHARMA has posted a net profit of Rs 11 bn (up 446.1% YoY). Sales on the other hand came in at Rs 72 bn (up 16.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

CIPLA Announces Quarterly Results (1QFY19); Net Profit Up 4.7% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, CIPLA has posted a net profit of Rs 4 bn (up 4.7% YoY). Sales on the other hand came in at Rs 39 bn (up 11.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

As the Rupee Takes a Record Plunge, These Pharma Stocks Gain the Most(Sector Info)

Sep 5, 2018

Most pharma stocks were trading with gains amid rupee's fresh fall. Does that mean pharma stocks are back in vogue?

Why Arun Jaitley's Demonetisation Defence Doesn't Add Up(Vivek Kaul's Diary)

Sep 5, 2018

The tax collected has gone up a little but the question is at what cost.

The Cream of Small Cap Stocks(Profit Hunter)

Sep 5, 2018

Akin to skimming the cream off milk, one needs to learn to skim the cream off small cap stocks.

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Sep 18, 2018 (Close)

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS